Board of Directors

Oncology Venture is working with a board
of highly skilled individuals

Duncan Moore

Chairman of the board, independent board member

Moore, born 1959, is a board member of Oncology Venture A/S, previously he served as chairman of Oncology Venture Sweden AB (publ) since 2015. Moore is a partner in the company East West Capital Partners and has previously worked as Global Head of Healthcare Research at Morgan Stanley. Duncan has over twenty years experience in capital markets analysis within health care.  

Independent in relation to the Company and its management and the Company’s major shareholders. 

Number of shares: 26 651
Number of warrants: 

Frank Knudsen

Deputy Chairman of the board, independent board member

Frank Knudsen, born 1958, has been Chairman of the Board of Directors in Oncology Venture A/S from April 2015- December 2018 and now serves as a deputy Chairman. Frank Knudsen has, along with others, been responsible for life science investments in SEED Capital Denmark K/S and he has also been responsible for the administration and completion of the national finance system for patenting and licensing of research from the universities in Denmark. Presently, Frank Knudsen is director of finance and administration in a private medical practice specializing in gastroenterology.

Independent in relation to the Company and its management and the Company’s major shareholders. 

Number of shares: 8 000.
Number of warrants: 100 000.

Peter Buhl Jensen

Chief Executive Officer at Oncology Venture

 

Dr. Buhl Jensen, born 1955, is MD, DMSc and a professor emeritus in clinical oncology.

Peter Buhl Jensen is a successful entrepreneur, innovating within the drug development field.

As the former CEO and co-founder of TopoTarget A/S, Peter successfully spearheaded the company’s IPO at the Copenhagen stock exchange. He ensured the development, approval, and launch of the oncology product Totect®/Savene® in USA and in Europe. Peter led the establishment of sales forces in both market regions.

Peter has been responsible for entering several license agreements, such as those related to Belinotstat, the lead product of Topotarget. Peter has been on the board of Oncology Venture since 2012.

Number of shares: Buhl Krone Holding (80 % owned by Peter Buhl Jensen) owns a total of 5 187 516 shares in Oncology Venture A/S.

Number of warrants: 315 000.

 

Steen Knudsen

Chief Science Officer at Oncology Venture

Steen Knudsen, born 1961, is the founder of Oncology Venture A/S and the inventor of DRP®. The Drug Response Prediction Platform is Oncology Venture’s core technology and science platform. Knudsen is a professor emeritus of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. Steen has been a board member since 2004.

Number of shares: 6 168 680.
Number of warrants: 0.

Magnus Persson

Independent board member

Dr Persson, born 1960, brings 20 years of international experience from leadership in Life Science innovation, development and financing. He has been a partner in two Life Sciences Venture Capital firms, one with its base in Sweden and with global reach and one in The Bay Area in California. Magnus was previous CEO at Karolinska Institutet Holding AB.

Magnus has extensive experience from medicine, life sciences and biotech financing. He has led development teams on Phase II and III programs in the Pharmaceutical Industry. He has founded, and led private as well as public biotech and medtech companies as Chairman of the Board, Board Director and CEO in the Nordic Countries, Europe and USA.

All in all, he has more than 100 Board years of experience in the life science industry. Magnus has led audit and remuneration committees and several successful recruitment processes for senior management positions. He has a vast international network in the science and biotech financing communities Magnus has been on the board of Oncology Venture since 2014.

Independent in relation to the Company and its management and the Company’s major shareholders.

Number of shares: 0.
Number of warrants: 135 360.

Carani Sanjeevi

Professor at Karolinska Institutet, independent board member

Dr. Carani, born 1958, is a member of the Board of Directors of Oncology Venture A/S since 2018, previously a board member of Oncology Sweden AB (publ) since 2015. Carani is a professor at Karolinska Institute and for several years has been head of the Molecular Immunogenetics Research Group at Karolinska University Hospital in Stockholm.  

Independent in relation to the Company and its management and the Company’s major shareholders.

Number of shares: 0.
Number of warrants: 135 360.